By Brooklyn Neustaeter, CTVNews.ca Editor
Toronto, Ontario (TVC network) – A new study found that people who received the Moderna COVID-19 mRNA vaccine are less likely to experience breakthrough infections compared to those who received the Pfizer-BioNTech mRNA vaccine.
The study, led by researchers at Case Western Reserve University in Cleveland, also found that people who received the Moderna vaccine were less likely to be hospitalized from a breakthrough infection than people who received the Moderna vaccine. Pfizer.
The findings were published Thursday in the peer-reviewed Journal of the American Medical Association.
A breakthrough infection occurs when an individual tests positive for COVID-19 more than 14 days after completing the recommended series of a two-dose COVID-19 vaccine.
According to the study, researchers examined the electronic health records of more than 637,000 fully vaccinated patients from 63 healthcare organizations across the United States, analyzing breakthrough COVID-19 infections, hospitalizations and rates. mortality between July and November 2021, when the Delta variant was the dominant viral strain circulating in the communities.
According to the study, incidents of breakthrough infections were included if the person had not previously been infected with COVID-19 or received a booster shot.
The researchers say the records included fully vaccinated patients from various geographic backgrounds, ages, races and ethnicities, income levels and insurance groups.
Breakthrough COVID infections, hospitalization, and mortality associated with the Delta variant were compared between Moderna mRNA vaccine recipients and Pfizer mRNA vaccine recipients while accounting for patient characteristics and varying time since vaccination,” said Rong Xu, study author and professor of bioinformatics at Case Western. , in a press release.
The study found that the “monthly incidence rate” of breakthrough cases was higher among those who received the Pfizer vaccine, compared to Moderna.
For example, researchers reported that data showed 2.8 breakthrough cases per 1,000 Americans among people vaccinated with Pfizer, compared to 1.6 cases among Moderna recipients in November 2021.
Regarding hospitalizations, the study found that the 60-day rate for Moderna recipients was 12.7%, compared to 13.3% for those who received the Pfizer vaccine.
However, the study says there was “no significant difference” in death rates between recipients of the two vaccines.
The findings come after some Ontario pharmacies reported earlier in January that people were quitting after being told they would receive the Moderna vaccine rather than Pfizer’s for their booster shot.
The study authors argue that the two vaccines are effective despite the difference in breakthrough rates. They say more research is needed in the future to assess these levels after booster doses.
“Although there is a difference in breakthrough infections, both vaccines are highly protective against SARS-COV2 infection and especially against the most severe consequences of infection,” said the co-author of the study, Pamela Davis, in the release.
Note: This content is subject to a strict local market embargo. If you share the same market as the contributor of this article, you cannot use it on any platform.